The WisdomTree Bianco Total Return Fund seeks to track the price and yield performance, before fees and expenses, of the Bianco Research Fixed Income Total Return Index.

WisdomTree has recently launched the WisdomTree Portfolio Solutions program, with three primary pillars: Portfolio Consultations, Model Portfolios and Custom Model Portfolios. In today’s fast-paced ...

With the Fed moving into a rate-cutting cycle, many investors are thinking about how to move from cash into longer-duration fixed income investments. Within our fixed income Model Portfolios, we have ...

SMCI’s 30% stock drop, due to a short-seller report, creates potential opportunities for competitors like Dell and HPE to step in and grab market share. The AI server market is expected to grow to ...

The Federal Reserve (Fed) began its rate-cutting cycle with a 50 basis-point (bp) cut at today’s FOMC meeting, bringing the new Fed Funds target range to 4.75%–5% ...

Corporate tax rate changes, like the 2017 TCJA, significantly boosted corporate earnings, especially for small-cap companies reliant on domestic revenue. Sectors such as Communication Services and ...

WisdomTree U.S. SmallCap Quality Dividend Growth Fund seeks to track the investment results of dividend-paying small-cap companies with growth characteristics in the U.S. equity market. Learn more ...

The WisdomTree Interest Rate Hedged High Yield Bond Fund seeks to track the price and yield performance, before fees and expenses, of the WisdomTree U.S. High Yield Corporate Bond, Zero Duration Index ...

Despite tight monetary policy, the economy shows resilience, with decelerating inflation and a cooling labor market. Inflation pressures are decreasing, with goods inflation returning to normal levels ...

Investor sentiment in commodity markets has reached a five-year low, presenting potential opportunities for contrarian investors. Potential opportunities and challenges exist in industrial metals, ...

The biotechnology sector has not seen a sustained rally in 2024 despite initial optimism and ongoing progress. Sarepta Therapeutics’ Elevidys, a $3.2 million gene therapy for Duchenne muscular ...